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Therapeutic effect of Cerebrolysin on reducing impaired 
cerebral endothelial cell permeability
Hua Tenga,*, Chao Lia,*, Yi Zhanga, Mei Lub, Michael Choppa,c,  
Zheng Gang Zhanga, Melanie Melcher-Mourgasd and Burkhard Fleckensteind   
Cerebrolysin has been shown to promote neurovascular 
protection and repair in preclinical models of stroke 
and neural injury and is demonstrating promise for 
stroke and neural injury therapeutic application in the 
clinic. The effect of Cerebrolysin on the human cerebral 
endothelial cell function has not been investigated. 
Using an in-vitro cerebral endothelial cell permeability 
assay and western blot analyses of tight junction and 
proinflammatory and procoagulant proteins, the present 
study showed that tissue plasminogen activator (tPA) and 
fibrin substantially impaired human cerebral endothelial 
cell barrier function and increased permeability, which 
persisted for at least 24 h. western blot analysis revealed 
that tPA and fibrin significantly increased proinflammatory 
and procoagulation proteins of intercellular adhesion 
molecule 1, high mobility group box 1, tumor necrosis 
factor α and phosphorylated nuclear factor kappa B-p65, 
and significantly reduced tight junction proteins zonular 1, 
occludin and claudin. However, Cerebrolysin significantly 
diminished and reversed tPA- and fibrin-impaired 
endothelial cell permeability, which was associated 
with significant reductions of tPA- and fibrin-augmented 
proinflammatory and procoagulation proteins and 
significant elevations of tPA- and fibrin-decreased tight 
junction proteins. The beneficial effect of Cerebrolysin 
appears specific because cerebroprotein hydrolysate, 
with a distinct peptide composition, failed to show 
the reduction of tPA- and fibrin-impaired permeability. 
These data indicate that cererbrolysin has a therapeutic 
effect on tPA- and fibrin-impaired cerebral endothelial 
cell permeability by reducing proinflammatory and 
procoagulation proteins and by elevating tight junction 
proteins. NeuroReport 32: 359–366 Copyright © 2021 The 
Author(s). Published by Wolters Kluwer Health, Inc.
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Introduction
Cerebrolysin is a neuropeptide preparation that mim-
ics the action of endogenous neurotrophic factors in the 
brain [1,2]. Preclinical studies show that Cerebrolysin has 
neuroprotective and neurorestorative therapeutic effects 
on stroke and traumatic brain injury (TBI) [3–5].
Cerebral endothelial cells play an important role in 
blood–brain barrier (BBB) homeostasis and in mediating 
brain injury, including stroke and TBI [6]. Tissue plas-
minogen activator (tPA) lyses fibrin via plasmin activity 
and is used to treat patients with acute ischemic stroke 
within 4.5 h after stroke onset; however, tPA increases the 
risk of hemorrhagic transformation mainly by increasing 
BBB permeability [7]. Soon after stroke onset fibrinogen/
fibrin mediates cerebral vascular thrombotic formation 
that contributes to expanding the ischemic core, leading 
to diminished salvageable brain tissue [8]. Additionally, 
fibrin directly induces proinflammatory responses, which 
promote disruption of the BBB and parenchymal cell 
damage [9]. Thus, pharmacological agents aimed at 
reduction of impaired BBB integrity by tPA, fibrin, or tPA 
along with fibrin may potentially treat stroke, TBI and 
other neurological diseases with disruption of the BBB. 
Accordingly, using an in-vitro model of human cerebral 
endothelial cell permeability, the present study investi-
gated whether Cerebrolysin has beneficial effects on cell 
permeability impaired by tPA and fibrin.
Materials and methods
Cerebrolysin (EVER Pharma, 4866 Unterach, Austria) 
and cerebroprotein hydrolysate (Huajin Pharmaceuticals, 
Hangzhou, Zhejiang, China) were supplied by EVER 
Pharma. Primary human brain microvascular endothelial 
cells (P3) were purchased from ScienCell (Cat#: 1000, 
Carlsbad,  California, USA) and cultured with endothe-
lial cell culture medium (ScienCell, Cat#: 1001). Passage 
four cells were employed in the present study. Prior to 
experiments, the purity of endothelial cells was verified 
by immunocytochemistry and all cells were CD31 pos-
itive, a marker of endothelial cells [10]. We previously 
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demonstrated using a transendothelial electrical resist-
ance assay that primary cerebral endothelial cells exhibit 
membrane resistance [11].
Cerebral endothelial cell permeability 
Endothelial cell permeability was measured according 
to published protocols with minor modification [12]. 
Briefly, the human cerebral endothelial cells (5 × 104/
well) were seeded in the insert of a transwell (0.4 µm 
pore, 3413, Costar) for 5 days to generate an endothelial 
monolayer. Fluorescent-conjugated dextran (70 kDa, 
0.5 mg/ml, D1830, Thermo Fischer Scientific, Waltham, 
Massachusetts, USA) was added into the inner cham-
ber of the trans-well for 30 min. Fluorescent signals at 
the outer chamber (the bottom well) were measured 
at wavelengths of 595 and 615 nm using a plate reader 
Fig. 1
A schematic shows an in-vitro endothelial cell permeability assay (a). Quantitative data of human endothelial cell permeability after treatment with 
Cerebrolysin at various concentrations alone and with tissue plasminogen activator (tPA) (b), as well as with fibrin (c), respectively. Western blot 
showed protein levels in the individual experimental groups treated with Cerebrolysin alone and in combination with tPA (d) or fibrin (e), respec-
tively. Data were acquired from three individual experiments and each individual experiment was performed in triplicate. * P < 0.001 vs. PBS, # 
P < 0.001 vs. tPA or fibrin and + P < 0.01 vs. indicated groups. FITC, fluorescent-conjugated; HMG1, high mobility group box 1; ICAM1, intercellu-
lar adhesion molecule 1; TNFα, tumor necrosis factor α.
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(Packard, Packard Bioscience Company, Meriden, 
Connecticut, USA). The trans-endothelial permeabil-









) control × 100% [13].
Western blot 
Total proteins in the endothelial cells were extracted 
and protein concentration was determined using a bicin-
choninic acid kit (23227, Thermo Fisher Technology). 
The following primary antibodies were used: mouse mAb 
against intercellular adhesion molecule 1 (ICAM1, 1:1,000, 
ab171123, Cambridge, Massachusetts, USA, Abcam), rab-
bit mAb against high mobility group box 1 (HMGB1, 
1:1,000, ab79823, Abcam), rabbit polyclonal antibodies 
against tumor necrosis factor α (TNFα, 1:1,000, 3707, Cell 
Signaling Technology, Cambridge, Massachusetts, USA), 
rabbit mAb against phosphorylated nuclear factor kappa 
B (NFκB)-p65 (NFκB-p65, 1:1,000, 8242, Cell Signaling 
Technology), rabbit polyclonal antibodies against zonular 
1 (ZO1, 1:1,000, 5406, Cell Signaling Technology), rabbit 
polyclonal antibodies against occludin (1:1,000, ab31721, 
Abcam) and rabbit polyclonal antibodies against claudin-5 
(1:1,000, ab15106, Abcam). Mouse mAb against β-actin 
(1:4,000, ab8226, Abcam) was used as the loading control. 
Horseradish peroxidase-conjugated secondary antibodies 
(1:2000) were used. The intensity of individual bands on 
western blots was measured and quantified by means of 
Image J software.
Reversed-phase HPLC analysis 
Reversed-phase HPCL (RP-HPLC) was used to ana-
lyze the profiles of Cerebrolysin and cerebroprotein 
hydrolysate. Briefly, the chromatographic separation was 
performed on an ACQUITY UPLC H-Class instrument 
(Waters) using a SPHERISORB OD2 column (4.0 mm 
I.D. × 250 mm, 5 μm particle size; 80 Å pore size, Waters). 
Eluents were (A) 0.1% trifluoroacetic acid (TFA) in 
pure water, (B) 80:20 (v/v) 0.085% TFA in acetonitrile: 
0.1% TFA in pure water. Peptides were separated using 
a linear gradient.
Experimental protocols 
To examine a dose-response of Cerebrolysin on tPA or 
fibrin-induced impairment of endothelial cell perme-
ability, Cerebrolysin at 5, 10, 20, 40 and 80 μl/ml either 
alone or along with human recombinant tPA (10 µg/ml) 
Fig. 2
The effect of Cerebrolysin and cerebroprotein hydrolysate alone and 
combined with tissue plasminogen activator (tPA) on endothelial mon-
olayer permeability. Data were acquired from three individual experi-
ments and each experiment was performed in triplicate. * P < 0.001 vs. 
PBS, # P < 0.001 vs. tPA or fibrin, and + P < 0.01 vs. indicated groups.
Fig. 3
Representative Western blot and quantitative data of endothelial cells treated with Cerebrolysin alone and in combination with tissue plasmino-
gen activator (tPA). Data were acquired from three individual experiments and each experiment was performed in triplicate. * P < 0.001 vs. PBS, 
# P < 0.001 vs. tPA and + P < 0.01 vs. indicated groups. For claudin-5, P = 0.01 Cerebrolysin/tPA vs. PBS. HMG1, high mobility group box 1; 
ICAM1, intercellular adhesion molecule 1; TNFα, tumor necrosis factor α; ZO1, zonular 1.
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or fibrin (1.5 µg/ml) were added into the transwells for 
24 h, and the endothelial cell permeability was measured. 
Cerebral endothelial cells treated with the same volume 
of PBS were used as control. The dose (10 µg/ml) of tPA 
used in the present study is comparable to a dose tPA 
(10.7 µg/ml) used for the treatment of patients with acute 
ischemic stroke [14]. A dose of 1.5 µg/ml fibrin used in 
the present study is consistent with the in-vivo fibrin 
levels found under pathological conditions of thrombo-
sis and BBB impairment [8,15]. The optimal effective 
Cerebrolysin treatment dose was determined and used 
in the following studies. Three individual experiments 
were performed and each individual experiment was per-
formed in triplicate.
As a control for the specificity of Cerebrolysin in reduc-
ing endothelial cell permeability, cerebroprotein hydro-
lysate [16] was used at the same dosage as Cerebrolysin 
(20 μl/ml).
To examine whether Cerebrolysin or cerebroprotein 
hydrolysate reverses tPA- or fibrin-impaired endothelial 
cell permeability, the cells were first treated with tPA 
(10 μg/ml) or fibrin (1.5 µg/ml) and 24 h later the cells 
were treated with Cerebrolysin for 24 h. After which, the 
endothelial cell permeability was measured.
To analyze the treatment effects on cerebral endothe-
lial proteins, total proteins were extracted from cere-
bral endothelial cells treated using the aforementioned 
protocols.
Statistical analysis
Analysis of variance was performed and the Tukey test 
was used to adjust multiple group comparisons. A value 
of P < 0.05 was considered significant. Data are presented 
as mean ± SD.
Results
Cerebrolysin diminishes tissue plasminogen activator-
impaired cell permeability
Using an in-vitro endothelial cell permeability assay 
(Fig.  1a), we first examined the effect of Cerebrolysin, 
tPA and fibrin, respectively, on endothelial cell permea-
bility. We found that placement of tPA (Fig. 1b) or fibrin 
(Fig.  1c) onto human cerebral endothelial cells signif-
icantly increased endothelial cell leakage compared 
with the PBS control group. However, the application of 
Cerebrolysin at 10 and 20 µl/ml, but not 5, 40 and 80 µl/
ml significantly reduced the cell leakage induced by tPA 
(Fig. 1b) or fibrin (Fig. 1c).
Western blot analysis showed that tPA (Fig. 1d) or fibrin 
(Fig.  1e) significantly elevated inflammatory and pro-
coagulant proteins which induce thrombosis and vas-
cular injury, including ICAM1, HMGB1, TNFα and 
NFκB-p65. However, Cerebrolysin substantially reduced 
these proteins elevated by tPA (Fig. 1d) or fibrin (Fig. 1e). 
Cerebrolysin by itself also decreased some of the listed 
proteins compared to the PBS control group (Fig. 1d and 
e). Interestingly, Cerebrolysin at 10 and 20 µl/ml reduced 
the tPA, but not the fibrin, augmented ICAM1 (Fig. 1d and 
e). Compared with Cerebrolysin at 10 µl/ml, Cerebrolysin 
at 20 µl/ml significantly reduced tPA-increased NFκB-p65 
(Fig. 1d) and fibrin-increased TNFα (Fig. 1e), respectively. 
Together with cell permeability results, Cerebrolysin at 
20 µl/ml, compared to the other Cerebrolysin doses, exhib-
ited the most robust beneficial effect on the tPA and fibrin 
impaired cerebral endothelial cells. Thus, Cerebrolysin at 
20 µl/ml was selected for the subsequent experiments.
Fig. 4
Representative western blot and quantitative data of endothelial cells treated with cerebroprotein hydrolysate alone and in combination with tissue 
plasminogen activator (tPA). Data were acquired from three individual experiments and each individual experiment was performed in triplicate. * 
P < 0.001 vs. PBS. HMG1, high mobility group box 1; ICAM1, intercellular adhesion molecule 1; TNFα, tumor necrosis factor α; ZO1, zonular 1.
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Fig. 5
Cerebrolysin, but not cerebroprotein hydrolysate, reversed tissue plasminogen activator (tPA)- (a) and fibrin- (b) increased endothelial monolayer 
permeability. Representative western blot and quantitative data of endothelial cells treated with Cerebrolysin and cerebroprotein hydrolysate after 
tPA (c) and fibrin (D) damage. Data were acquired from three individual experiments and each individual experiment was performed in triplicate. * 
P < 0.001 vs. PBS, and # P < 0.001 vs. tPA or fibrin. For TNF α P = 0.01 Cerebrolysin/tPA vs. PBS; for Claudin-5 P = 0.048 Cerebrolysin/tPA vs. 
tPA and P = 0.042 Cerebrolysin/fibrin vs. fibrin. HMG1, high mobility group box 1; ICAM1, intercellular adhesion molecule 1; TNFα, tumor necro-
sis factor α; ZO1, zonular 1.
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Cerebrolysin at 20 µl/ml significantly reduced tPA aug-
mented permeability by more than 50%, whereas cere-
broprotein hydrolysate at 20 µl/ml only decreased tPA 
augmented permeability by 20% (Fig. 2). The reduction 
of endothelial cell permeability with Cerebrolysin was 
significantly greater than with cerebroprotein hydrolysate 
(Fig. 2). Western blot analysis showed that Cerebrolysin 
significantly diminished tPA-increased proinflammatory 
and procoagulant proteins and suppressed tPA-reduced 
tight junction proteins (Fig. 3). However, cerebroprotein 
hydrolysate at 20 µl/ml in combination with tPA did not 
significantly affect tPA-altered proteins (Fig.  4). These 
data suggest that the beneficial effect of Cerebrolysin is 
specific compared with cerebroprotein hydrolysate.
Cerebrolysin reverses tissue plasminogen activator- 
and fibrin-impaired cell permeability
Next, we examined whether Cerebrolysin reverses 
tPA- or fibrin-induced cerebral endothelial cell perme-
ability. The tPA or fibrin treatment resulted in signif-
icantly increased endothelial cell permeability, which 
persisted for at least 24 h, compared with PBS control 
(Fig.  5a and b). Importantly, when Cerebrolysin was 
added at 24 h after the tPA or fibrin treatment, it signifi-
cantly reduced augmented permeability (Fig. 5a and b), 
whereas cerebroprotein hydrolysate did not significantly 
decrease tPA- or fibrin-increased permeability (Fig.  5a 
and b). Western blot analysis of the endothelial cells 
showed that compared to PBS control, tPA and fibrin 
significantly increased ICAM1, HMGB1, TNFα and 
NFκB-p65, and significantly reduced ZO1, occludin and 
claudin-5, whereas Cerebrolysin, but not cerebroprotein 
hydrolysate, significantly reduced ICAM1 and HMGB1 
and significantly increased tight junction proteins ZO1, 
occludin and claudin (Fig. 5c and d).
To obtain insight into this profound difference in the 
reduction of inflammatory markers and protection of 
endothelial cells from tPA or fibrin, between Cerebrolysin 
and cerebroprotein hydrolysate, RP-HPLC analysis of 
Cerebrolysin and cerebroprotein hydrolysate peptides 
was conducted (Fig. 6). Overall, there was a clear differ-
ence in the chromatographic profiles of both samples, 
demonstrating a complex overall composition and a clear 
difference of peptide constituents between Cerebrolysin 
and cerebroprotein hydrolysate.
Discussion
Using an in-vitro human cerebral endothelial cell per-
meability assay, the present study demonstrated that 
Cerebrolysin has a therapeutic effect on tPA- and 
fibrin-impaired cell permeability, even when Cerebrolysin 
was added at 24 h after cerebral endothelial cell injury. 
Cerebrolysin substantially suppressed proinflammatory 
and prothrombotic proteins and augmented tight junction 
proteins in cerebral endothelial cells treated with tPA or 
fibrin. These in-vitro data suggest that Cerebrolysin has a 
potent therapeutic effect on impaired cerebral endothe-
lial cell permeability by reducing endothelial cell inflam-
matory and prothrombotic proteins and by elevating tight 
junction proteins.
The present study showed that tPA and fibrin act as nox-
ious stimuli to disrupt human cerebral endothelial cell 
integrity, likely, by reducing tight junction proteins, and 
that impaired endothelial permeability persists for at 
least 24 h after the initial stimulation. In addition, tPA and 
fibrin induce proinflammatory and prothrombotic pro-
teins in human cerebral endothelial cells. These data are 
consistent with findings that treatment of acute ischemic 
stroke with tPA reduces BBB integrity, consequently 
increasing the risk of a cerebral hemorrhage, whereas 
fibrinogen/fibrin triggers proinflammatory and prothrom-
botic proteins [7,17,18]. The dose of tPA used in the 
present study is comparable to the dose of tPA employed 
for the treatment of patients with acute ischemic stroke 
[14]. Although fibrinogen circulates in the plasma at a 
concentration of 2–4 g/L, fibrin is undetectable under 
the physiological conditions. However, there is abun-
dant fibrin deposition in the brain after brain injury and 
Fig. 6
Overlaid Peptide Fingerprint chromatograms of Cerebrolysin (black) and cerebroprotein hydrolysat (green). Clear differences in the peak pattern 
and intensity were detected between the two samples.
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neurodegenerative diseases, and the increase in fibrin 
deposition has been used as an indication of vascular 
thrombosis and impairment of the BBB [8,15]. Thus, the 
in-vitro model of human cerebral endothelial permeabil-
ity employed in our study appears clinically relevant.
Preclinical and clinical studies of stroke and TBI have 
shown neuroprotective and neurorestorative effects of 
Cerebrolysin [3–5]. As a neuropeptide preparation that 
mimics the action of endogenous neurotrophic factors, 
Cerebrolysin impacts multiple brain repair processes to 
improve neurological recovery, including angiogenesis, 
neurogenesis, oligodendrogenesis and axonal outgrowth 
[19]. The present study provides additional evidence that 
Cerebrolysin directly acts on cerebral endothelial cells to 
diminish and to reverse tPA and fibrin evoked endothe-
lial cell permeability, when Cerebrolysin is applied con-
currently as tPA and fibrin or even when Cerebrolysin 
is administered 24 h after the initial treatments, respec-
tively. This effect appeared to be specific for Cerebrolysin 
as a control peptide mixture (cerebroprotein hydrolysate) 
with a substantially different peptide composition did 
not display such beneficial effects.
Cerebral endothelial cells play an important role in BBB 
homeostasis and in mediating brain injury and degener-
ative diseases, including stroke, TBI and dementia [6]. 
The beneficial effects of Cerebrolysin underlying neu-
rological injuries and degenerative diseases have been 
demonstrated [3–5,20,21], whereas the present in-vitro 
data suggest that Cerebrolysin-improved cerebral 
endothelial cell function may also contribute to its ther-
apeutic effect.
Tight junction proteins in cerebral endothelial cells, 
including ZO-1, occludin and claudin-5 are critical to 
the formation and maintenance of BBB integrity [6]. 
Proinflammatory and procoagulant proteins, including 
HMGB1, TNFα, ICAM1 and NFkB, disrupt the BBB 
[22–25]. In parallel with functional data, the present study 
showed that tPA and fibrin trigger elevation of proin-
flammatory and procoagulant proteins, and reduce tight 
junction proteins in the endothelial cells. Cerebrolysin 
is given concurrently with tPA or fibrin robustly dimin-
ished proinflammatory and procoagulant proteins and 
elevated tight junction protein levels to their basal level 
in the endothelial cells. It is likely that proinflamma-
tory and procoagulant proteins lead to the downregula-
tion of tight junction proteins [23]. Importantly, tPA and 
fibrin altered proteins persisted for at least 24 h after 
the initial treatment; however, even delayed treatment 
with Cerebrolysin 24 h after endothelial injury reversed 
these altered proteins. These protein data suggest that 
Cerebrolysin not only suppresses the effects of tPA and 
fibrin on triggering endothelial injury proteins but also 
reverses tPA- and fibrin-altered proteins, which provides 
potential mechanisms underlying how Cerebrolysin 
achieves its beneficial effects on the improvement of 
cerebral endothelial cell integrity. Additional studies are 
warranted to further investigate these mechanisms.
In summary, the present in-vitro study demonstrates 
that Cerebrolysin, even at a delayed administration time 
point, has beneficial effects on reducing tPA and fibrin 
impaired cerebral endothelial cell permeability and 
reducing increased pro-inflammatory and procoagulation 
proteins.
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